RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...